VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AIMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AIMDAinos, Inc.
$1.88$9M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. AIMD
  4. Financial Ratios

Ainos, Inc. (AIMD) Financial Ratios

Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -128.0%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

AIMD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$9M$7M$22M$42M$42M$476M—————
Enterprise Value$19M$18M$30M$46M$42M$478M—————
P/E Ratio →-0.54——————————
P/S Ratio68.5656.411045.31343.9912.01800.19—————
P/B Ratio1.060.931.401.721.2246.66—————
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

AIMD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—141.651436.41377.3911.85803.34—————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

AIMD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin-3767.2%-3767.2%-153.7%-207.8%39.9%69.0%31.9%25.2%16.5%76.0%—
Operating Margin-11268.3%-11268.3%-66772.2%-10815.0%-397.1%-650.5%-8696.7%-13472.1%-1717.2%-231.0%—
Net Profit Margin-11897.0%-11897.0%-71702.3%-11277.0%-398.0%-654.0%-8758.2%-13487.2%-1722.3%-246.0%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-128.0%-128.0%-74.4%-46.6%-62.5%-83.1%—-551.9%-222.9%-131.1%—
ROA-59.5%-59.5%-49.0%-39.9%-35.9%-18.9%-338.6%-153.6%-71.3%-44.8%-231.1%
ROIC-50.2%-50.2%-39.8%-31.7%-45.5%-47.7%—————
ROCE-62.7%-62.7%-50.0%-40.5%-62.3%-82.4%—-551.2%-222.3%-123.1%—

AIMD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.451.450.770.240.040.36——0.701.88—
Debt / EBITDA———————————
Net Debt / Equity—1.400.520.17-0.020.18——-1.05-2.32—
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-19.65-19.65-23.11-94.50-260.67-207.07-141.39-1785.78-336.78-15.41-232.36

AIMD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.061.061.101.851.150.070.070.591.781.140.21
Quick Ratio0.780.781.061.720.910.070.070.591.781.130.19
Cash Ratio0.390.390.981.410.750.060.020.541.741.090.11
Asset Turnover—0.010.000.000.090.010.060.020.050.11—
Inventory Turnover16.2416.240.372.243.55—3.732.12—2.661.77
Days Sales Outstanding—0.060.991.3620.90——————

AIMD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%—————
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%—————
Shares Outstanding—$4M$10M$4M$3M$2M$543079$2M$2M$2M$1M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity insolvency risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Disconnected Valuation Amidst Revenue Scarcity

According to recent market data, Ainos trades at a price-to-sales multiple of 63.09, a figure that appears detached from the company's negligible revenue base and suggests investors are pricing in speculative optionality rather than any tangible fundamental performance or established commercial trajectory in the diagnostic sector.

The elevated P/S ratio reflects a market valuation that is entirely decoupled from the firm's current inability to generate meaningful top-line growth. This valuation suggests that the market is assigning value to the company's intellectual property portfolio rather than its operational output, which warrants extreme caution given the lack of commercial scale.

Capital Erosion Reflects Unproductive Investment

As reported in financial statements, the company's ROIC has consistently remained in negative territory, reaching -10.7% in 2026Q1, which indicates that every dollar of capital deployed into the business is currently destroying shareholder value rather than generating any form of sustainable economic return.

The persistent negative return on capital is a direct consequence of high R&D spending that has yet to yield a commercially viable product. This trend suggests that the company is failing to achieve the necessary efficiency to justify its ongoing capital requirements, leaving little evidence of a path toward compounding returns.

Working Capital Inefficiency Hinders Operational Flow

Based on quarterly filings, the company's asset turnover remains effectively at zero, highlighting a structural inability to convert its asset base into revenue, while the erratic nature of its inventory and receivables management suggests a lack of a cohesive, repeatable operational cycle for its diagnostic products.

The absence of meaningful asset turnover confirms that the company's infrastructure is currently underutilized and disconnected from market demand. Investors should monitor whether the firm can transition from a prototype-heavy model to one that demonstrates basic operational efficiency, as current metrics suggest a significant disconnect between investment and output.

Debt Burden Compounding Financial Fragility

As indicated by the company's reported figures, the debt-to-equity ratio has climbed to 1.93 in 2026Q1, a concerning trend that suggests the firm is increasingly relying on external leverage to fund its operations in the absence of internal cash generation or a stable revenue stream.

The rising leverage, combined with deeply negative interest coverage, indicates that the company's ability to service its obligations is severely compromised. This reliance on debt in a pre-revenue state significantly elevates the risk of insolvency and suggests that future financing will likely be highly dilutive to existing shareholders.

Misapplication of Price-to-Book Ratios

Market participants often rely on the price-to-book ratio of 0.98 to suggest the stock is undervalued, yet this metric is fundamentally misleading for Ainos because the book value is heavily inflated by intangible assets and goodwill that lack clear, realizable market value in a liquidation scenario.

Using P/B as a valuation anchor obscures the reality that the company's assets are primarily tied to unproven R&D projects rather than tangible, productive capital. A more appropriate focus would be the cash burn rate relative to total liquidity, which provides a more accurate assessment of the company's survival risk.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AIMD — Frequently Asked Questions

Quick answers to the most common questions about buying AIMD stock.

What is Ainos, Inc.'s P/E ratio?

Ainos, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.

What is Ainos, Inc.'s ROE?

Ainos, Inc.'s return on equity (ROE) is -128.0%. The historical average is -92.5%.

Is AIMD stock overvalued?

Based on historical data, Ainos, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Ainos, Inc.'s profit margins?

Ainos, Inc. has -3767.2% gross margin and -11268.3% operating margin.